SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Director/PDMR Shareholding

3 May 2018 15:27

RNS Number : 0735N
Collagen Solutions PLC
03 May 2018
 

 

Collagen Solutions Plc

(the "Company")

3 May 2018

Director / PDMR Dealing

 

The Company today announces that on 3 May 2018, Lou Ruggiero, Chief Business Officer ("CBO") of the Company, was granted options (the "Options") over 2,000,000 ordinary shares of 1 pence each in the share capital of the Company ("Shares") exercisable at a price of 3.65 pence per Share.

 

The Options, will vest in three equal tranches on the first, second and third anniversaries of 16 April 2018, being the date of Mr. Ruggiero's appointment as CBO. Such vesting will be conditional on his continued employment. In addition, the ability to exercise any vested Options will be dependent on achieving a closing middle market price per Share of 10 pence at any time after the date of grant and on the Company delivering sustainable positive cash flows from operations for any period of six months. All Options will lapse after 10 years from the date of grant, being 3 May 2018.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilitiesand persons closely associated with them

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Lou Ruggiero

2

Reason for the notification

 

a)

Position/status

Chief Business Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Collagen Solutions Plc

b)

LEI

213800IFY1CVGRGETL95

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

 

Identification code

Options over Ordinary shares of 1p each

 

 

 

ISIN Code: GB00B94T6Y14

b)

Nature of the transaction

Grant of options over ordinary shares of 1p each exercisable at 3.65p per share

c)

Price(s) and volume(s)

 

Price(s): Volume(s):

 

3.65 pence 2,000,000

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

N/A

 

 

N/A

e)

Date of the transaction

03/05/2018

f)

Place of the transaction

Outside a trading venue

 

 

For further information please contact:

 

Collagen Solutions PlcJamal Rushdy, Chief Executive OfficerHilary Spence, Chief Financial OfficerLisa Baderoon, Head of Investor Relations

Tel: +44 (0) 141 648 9100Tel: +44 (0) 7721 413 496 or lisa.baderoon@collagensolutions.com

Cenkos Securities plc (NOMAD and Broker)Stephen KeysSteve Cox

Tel: +44 (0) 207 397 8900

Walbrook PRAnna DunphyHelen Cresswell

Tel: +44 (0) 20 7933 8780 or collagen@walbrookpr.comMob: +44 (0) 7876 741 001

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFKNDBQBKDQPK
Date   Source Headline
10th Mar 20152:56 pmRNSDirector/PDMR Shareholding
10th Mar 20157:03 amRNSRegulatory Approvals for Collagen Solutions Client
10th Mar 20157:03 amRNSTrading Statement and Acquisition Update
9th Jan 20157:00 amRNSInvestor Presentation
7th Jan 20154:04 pmRNSHolding(s) in Company
7th Jan 20157:00 amRNSCEO Presents at OneMedForum
5th Jan 20157:00 amRNSContract signed with Globus Medical Inc.
22nd Dec 20147:00 amRNSNew contract to supply Desu Medical
17th Dec 201410:54 amRNSHolding(s) in Company
15th Dec 20147:00 amRNSContract signed with Kyeron
12th Dec 201410:50 amRNSHolding(s) in Company
10th Dec 20147:00 amRNSSouthern Lights Biomaterials Acquisition Completed
24th Nov 201411:48 amRNSGrant of Options
21st Nov 20147:30 amRNSSchedule 1 - Collagen Solutions Plc
21st Nov 20147:00 amRNSAcquisition
21st Nov 20147:00 amRNSChange of Adviser
21st Nov 20147:00 amRNSHalf Yearly Report
22nd Oct 201412:30 pmRNSHolding(s) in Company
17th Oct 20147:00 amRNSJellagen Collaboration
10th Sep 201412:23 pmRNSHolding(s) in Company
3rd Sep 20147:00 amRNSAppointment to Scientific Advisory Board
27th Aug 201411:52 amRNSResult of AGM
29th Jul 20143:19 pmRNSHolding(s) in Company
18th Jul 20147:00 amRNSPosting of Annual Report & Notice of AGM
10th Jul 20147:00 amRNSFinal Results
3rd Jul 20147:00 amRNSChange of Registered Office
10th Jun 20147:00 amRNSExclusive Licencing of Intellectual Property
19th May 20147:00 amRNSProfessor Robert Brown joins as Scientific Adviser
15th May 20147:00 amRNSExcellagen® enters new clinical trial
26th Mar 201410:48 amRNSHolding(s) in Company
3rd Mar 20147:00 amRNSAppointment of Director
27th Dec 201312:25 pmRNSDirector Shareholding
27th Dec 201311:58 amRNSResult of GM
17th Dec 201310:00 amRNSAnnouncement by Cardium Therapeutics
16th Dec 20139:03 amRNSSchedule 1 - Healthcare Investment Opportunities
10th Dec 20137:00 amRNSHalf Yearly Report
10th Dec 20137:00 amRNSProposed acquisition
19th Aug 201311:06 amRNSHolding(s) in Company
1st Aug 20131:43 pmRNSHolding(s) in Company
2nd May 201312:00 pmRNSHolding(s) in Company
22nd Apr 201312:19 pmRNSHolding(s) in Company
9th Apr 201310:57 amRNSHolding in Company
8th Apr 20135:41 pmRNSHolding(s) in Company
5th Apr 20137:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.